Trial Profile
Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2020
Price :
$35
*
At a glance
- Drugs GLS 5300 (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions; First in man
- Sponsors GeneOne Life Science
- 25 Jul 2019 According to an Inovio Pharmaceuticals media release, positive results from this trial were published in The Lancet Infectious Diseases.
- 12 Mar 2019 According to Inovio Pharmaceuticals media release, Inovio expects to have clinical data from several Phase 1 vaccine programs published multiple publications in 2019: Ebola vaccine; MERS vaccine; HIV; and ZIka vaccine study in Puerto Rico.
- 31 Jul 2018 Status changed from active, no longer recruiting to completed.